

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 September 2001 (13.09.2001)

PCT

(10) International Publication Number
WO 01/66525 A1(51) International Patent Classification⁷: C07D 235/04, 249/18, A61K 31/4192, 31/4184, 31/445, A61P 31/12

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(21) International Application Number: PCT/SE01/00470

(22) International Filing Date: 6 March 2001 (06.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0005642.4 10 March 2000 (10.03.2000) GB

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BURROWS, Jeremy [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). CUMMING, John [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). MCINALLY, Thomas [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES



(57) Abstract: The invention concerns compounds of formula (I), wherein the variables are defined herein; processes for preparing them, compositions comprising them and their use in modulating CCR5 receptor activity.

WO 01/66525 A1

NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES

The present invention relates to bicyclic heteroaryl derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

5 Pharmaceutically active 1-(piperidin-4-yl)benzimidazole derivatives are disclosed in US3318900, WO97/40035, WO99/04794, WO99/36421, EP-A1-1069124 and J. Med. Chem. (1978) 21(11) 1116-1120.


10 Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. There are two classes of chemokine, C-X-C (α) and C-C (β) depending on whether the first two cystines are separated by a single amino acid (C-X-C) or are adjacent (C-C). CCR5 is an example of a β -chemokine receptor.

15 The CCR5 receptor is expressed on T-lymphocytes, monocytes, macrophages, dendritic cells, microglia and other cell types. These detect and respond to several chemokines, principally "regulated on activation normal T-cell expressed and secreted" (RANTES), macrophage inflammatory proteins (MIP) MIP-1a and MIP-1b and monocyte chemoattractant protein-2 (MCP-2).

20 This results in the recruitment of cells of the immune system to sites of disease. In many diseases it is the cells expressing CCR5 which contribute, directly or indirectly, to tissue damage. Consequently, inhibiting the recruitment of these cells is beneficial in a wide range of diseases.

25 CCR5 is also a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Blocking the receptor with a CCR5 antagonist protects cells from viral infection.

The present invention provides a compound of formula (I):



wherein

A is a 5, 6 or 7 membered ring comprising, respectively, 4, 5 or 6 carbons and one nitrogen which carries a substituent R¹. A being either saturated or including one endocyclic double bond;

X-Y is N=C(R⁵) or N=N;

5 J is N or CR^{2a}; K is N or CR^{2b}; L is N or CR^{2c}; M is N or CR^{2d}; provided that no more than 2 of J, K L and M are N;

R^{2a}, R^{2b}, R^{2c} and R^{2d} are, independently, hydrogen, halo, cyano, nitro, hydroxy, SH, S(O)_pR⁶, NR⁷R⁸, SO₂NR⁹R¹⁰, CONR¹¹R¹², NR¹³SO₂R¹⁴, NR¹⁵COR¹⁶, COR¹⁷, CO₂R¹⁸, NR¹⁹CONR²⁰R²¹, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkenyloxy, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl or heterocyclyl, or phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy, wherein any of the foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy;

10 R¹ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₈ alkenyl or C₃₋₈ alkynyl, each optionally substituted with haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl or heterocyclyl, or phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy, wherein any of the foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy;

15 R¹ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₈ alkenyl or C₃₋₈ alkynyl, each optionally substituted with one or more of: halo, hydroxy, cyano, nitro, C₁₋₆ alkoxy (itself optionally substituted by heterocyclyl or CONR⁶²R⁶³), C₃₋₇ cycloalkyl, NR²²R²³, C(O)R²⁴, NR²⁵SO₂R²⁶, NR²⁷C(O)R²⁸, SO₂NR²⁹R³⁰, CONR³¹R³², NR³³CONR³⁴R³⁵, S(O)_mR⁶⁴, heterocyclyl, heterocyclyloxy, aryl, aryloxy, heteroaryl, heteroaryloxy, 9H-fluorenyl (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl), 9H-xanthenyl

20 (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl) or dibenzo(a,d)cycloheptatrienyl (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl);

R³, R^{3a}, R⁴ and R^{4a} are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted by hydroxy or alkoxy), CO₂R³⁶ or CONR³⁷R³⁸ (wherein R³⁶, R³⁷ and R³⁸ are, independently, hydrogen or C₁₋₆ alkyl);

25 R⁵ is hydrogen, C₁₋₆ alkyl (optionally substituted with cyano, hydroxy, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, COR⁵⁸, SO₂NR⁵⁸R⁵⁹, C(O)NR⁷⁵R⁷⁶, NR⁷⁴COR⁶⁵, NR⁷³SO₂R⁶⁶, NHC(O)NR⁶⁷R⁷², NR⁶⁸R⁶⁹, SO₂R⁷⁷, C(O)R⁷⁸, heterocyclyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, heterocyclyl, heteroaryl, OR⁷⁹, SR⁷⁹, CONR³⁹R⁴⁰, COR³⁹, NR³⁹R⁴⁰,

30 (wherein R³⁹ and R⁴⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; and R⁷⁹ is C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl), NR⁷⁰SO₂R⁷¹ or

NR⁷⁰C(O)R⁷¹ (wherein R⁷⁰, R⁷³ and R⁷⁴ are, independently, hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or C₃₋₆ cycloalkyl; and R⁷¹ is C₁₋₆ alkyl, C₃₋₇ cycloalkyl, aryl or heteroaryl); R⁶⁴ is alkyl, cycloalkyl, aryl or heteroaryl;

R¹³, R¹⁵, R¹⁹, R²⁵, R²⁷, R³³, are, independently, hydrogen, C₁₋₆ alkyl or phenyl;

5 R⁶, R¹⁴ and R²⁶ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl), phenyl or heteroaryl;

R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹⁶, R¹⁷, R¹⁸, R²⁰, R²¹, R²², R²³, R²⁴, R²⁸, R²⁹, R³⁰, R³¹, R³², R³⁴, R³⁵, R⁵⁸, R⁵⁹, R⁶⁷, R⁶⁸, R⁶⁹, R⁷², R⁷⁵ and R⁷⁶ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, heterocyclyl, CONR⁶⁰R⁶¹, or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

10 unless specified otherwise, the foregoing aryl, phenyl and heteroaryl moieties are optionally substituted with halo, cyano, nitro, hydroxy, S(O)_qR⁴¹, NR⁴²R⁴³, SO₂NR⁴⁴R⁴⁵, CONR⁴⁶R⁴⁷, NR⁴⁸SO₂R⁴⁹, NR⁵¹COR⁵², COR⁵³, CO₂R⁵⁴, NR⁵⁵CONR⁵⁶R⁵⁷, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy;

15 R⁴⁸, R⁵¹ and R⁵⁵ are, independently, hydrogen, C₁₋₆ alkyl or phenyl;

R⁴¹, R⁴⁹ R⁶⁶ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

20 R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁵², R⁵³, R⁵⁴, R⁵⁶, R⁵⁷, R⁶⁰, R⁶¹, R⁶², R⁶³ and R⁶⁵ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

25 the pairs of substituents: R⁷ and R⁸, R⁹ and R¹⁰, R¹¹ and R¹², R²⁰ and R²¹, R²² and R²³, R²⁹ and R³⁰, R³¹ and R³², R³⁴ and R³⁵, R³⁷ and R³⁸, R³⁹ and R⁴⁰, R⁴² and R⁴³, R⁴⁴ and R⁴⁵, R⁴⁶ and R⁴⁷, R⁵⁶ and R⁵⁷, R⁵⁸ and R⁵⁹, R⁷⁵ and R⁷⁶, R⁶⁷ and R⁷² and R⁶⁸ and R⁶⁹ may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom;

30 R⁷⁷ and R⁷⁸ are, independently, N-linked heterocyclyl;

where for any of the foregoing heterocyclic groups having a ring $-N(H)-$ moiety, that $-N(H)-$ moiety may be optionally substituted by C_{1-4} alkyl (itself optionally substituted by hydroxy), $C(O)(C_{1-4}$ alkyl), $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂ or $SO_2(C_{1-4}$ alkyl);
m, p and q are, independently, 0, 1 or 2;

5 a ring nitrogen and/or sulphur atom is optionally oxidised to form an *N*-oxide and/or an *S*-oxide;
or a pharmaceutically acceptable salt thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers or geometric isomers). The present invention covers all such
10 isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as hydrochlorides, hydrobromides or acetates.

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

15 Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl or iso-propyl. Unless specified otherwise, alkyl groups preferably contain from 1 to 6 carbon atoms, especially from 1 to 4 carbon atoms.

Alkoxyalkyl is, for example, methoxymethyl, ethoxymethyl, 2-methoxyeth-1-yl or 2-ethoxyeth-1-yl.

20 Alkenyl and alkynyl groups and moieties are, for example, vinyl, allyl or propargyl.

Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl.

Acyl is, for example, carbonyl substituted by C_{1-6} alkyl or optionally substituted phenyl.

25 Halogen includes fluorine, chlorine, bromine and iodine. Preferably halogen is chlorine or fluorine.

Heterocyclyl is a non-aromatic 5 or 6 membered ring comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur. Heterocyclyl is, for example, piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl or tetrahydrofuryl.

30 Heteroaryl is an aromatic 5 or 6 membered ring comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur. Heteroaryl is, for example, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, furyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzo[b]furyl or benzo[b]thienyl.

Aryl is a carbocyclic aromatic ring system (for example phenyl or naphthyl).


Phenyl(C₁₋₄ alkyl) is, for example, benzyl or 2-phenyleth-1-yl. Phenyl(C₁₋₄ alkoxy) is, for example, benzyloxy. Heteroaryl(C₁₋₄ alkyl) is, for example, pyridylmethyl or pyrimidinylmethyl. Heteroaryl(C₁₋₄ alkoxy) is, for example, pyridylmethoxy or 5 pyrimidinylmethoxy.

Haloalkyl is, for example CF_3 . Haloalkoxy is, for example, OCF_3 .

When R^{39} and R^{40} join to form a ring the ring is, for example, a piperazinyl, piperidinyl, pyrrolidinyl or morpholinyl ring.


The ring A is, for example, pyrrolidinyl, piperidinyl (such as piperidin-4-yl), homopiperidinyl or 1,2,3,6-tetrahydropyridinyl. Preferably A is piperidinyl (such as piperidin-4-yl).

In one particular aspect the present invention provides a compound of formula (Ia):





wherein J, K, L, M, X, Y, R¹, R³ and R⁴ are as defined above.

15 In a further aspect the present invention provides a compound of formula (Ib) or (Ic):




wherein R^1 , R^{2a} , R^{2b} and R^5 are as defined above.

In a further aspect the present invention provides a compound of formula (Ib') or (Ic'):



wherein R¹ and R⁵ are as defined above; and the meanings of R^{2a'} and R^{2b'} are, independently, selected from the list recited above for R^{2a} and R^{2b}.

In another aspect the invention provides a compound of formula (Id):



5


wherein R¹ is C₁₋₁₀ alkyl optionally substituted with the substituents recited above; R^{2a} is as defined above; and R⁵ is hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, COR⁵⁸, SO₂NR⁵⁸R⁵⁹, phenyl or heteroaryl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, heterocycl, heteroaryl, OR⁷⁹, SR⁷⁹, CONR³⁹R⁴⁰, COR³⁹ or NR³⁹R⁴⁰, (wherein R⁵⁸ and R⁵⁹ are, independently, hydrogen or C₁₋₄ alkyl; R³⁹ and R⁴⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; R⁷⁹ is C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl); wherein the phenyl and heteroaryl groups are optionally substituted as above.

10

wherein R¹ is C₁₋₁₀ alkyl optionally substituted with the substituents recited above; R^{2a} is as defined above; and R⁵ is hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; R³⁹ and R⁴⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; R⁷⁹ is C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl); wherein the phenyl and heteroaryl groups are optionally substituted as above.

15

In another aspect the invention provides a compound of formula (Id'):




wherein R^1 is C_{1-10} alkyl optionally substituted with the substituents recited above; the meaning of $R^{2a'}$ is selected from the list recited above for R^{2a} ; and R^5 is hydrogen, C_{1-6} alkyl (optionally substituted with C_{3-7} cycloalkyl, COR^{58} , $SO_2NR^{58}R^{59}$, phenyl or heteroaryl), C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, heterocyclyl, heteroaryl, OR^{79} , SR^{79} ,

5 $CONR^{39}R^{40}$, COR^{39} or $NR^{39}R^{40}$, (wherein R^{58} and R^{59} are, independently, hydrogen or C_{1-4} alkyl; R^{39} and R^{40} are, independently, hydrogen, C_{1-6} alkyl (optionally substituted with C_{3-7} cycloalkyl, phenyl or heteroaryl), C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, phenyl or heteroaryl; R^{79} is C_{1-6} alkyl (optionally substituted with C_{3-7} cycloalkyl, phenyl or heteroaryl), C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, phenyl or heteroaryl); wherein the phenyl and


10 heteroaryl groups are optionally substituted as above.

In a further aspect the present invention provides a compound of formula (Ie):



wherein R^1 is C_{1-10} alkyl optionally substituted with the substituents recited above.

In yet another aspect the present invention provides a compound of formula (If):



15

wherein R^{79} is C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or heteroaryl; M^1 is a bond, $C(O)$, $S(O)_2$, $S(O)_2NH$ or $C(O)NH$; and M^2 is C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or heteroaryl; the phenyl and heteroaryl groups being optionally substituted as recited above.

In another aspect the present invention provides a compound of formula (I) or (Ia) wherein J is CR^{2a}; K is CR^{2b}; L is CR^{2c}; and M is N or CR^{2d}.

In another aspect the present invention provides a compound of formula (I) or (Ia) wherein X-Y is N=C(R⁵).

5 In a still further aspect the present invention provides a compound of formula (Ib) wherein R^{2a} and R^{2b} are, independently, hydrogen, halo, cyano, nitro, hydroxy, SH, S(O)_pR⁶, NR⁷R⁸, SO₂NR⁹R¹⁰, CONR¹¹R¹², NR¹³SO₂R¹⁴, NR¹⁵COR¹⁶, COR¹⁷, CO₂R¹⁸, NR¹⁹CONR²⁰R²¹, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkenyloxy, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl or heterocyclyl, or phenyl, 10 phenyl(C₁₋₄)alkyl, phenoxy, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy, wherein any of the foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy; R¹ is 2,4,6-trimethoxybenzyl, 2,4-dimethoxy-6-hydroxybenzyl, 3-(4-dimethylamino-phenyl)prop-15 2-enyl, (1-phenyl-2,5-dimethylpyrrol-3-yl)methyl, 2-phenylethyl, 3-phenylpropyl, 3-R/S-phenylbutyl, 3-cyano-3,3-diphenylpropyl, 3-cyano-3-phenylpropyl, 4-(N-methylbenzene-sulphonamido)-3-phenylbutyl, 4-(N-methylbenzamido)-3-phenylbutyl or 3,3-diphenylpropyl; R⁵ is hydrogen, C₁₋₆ alkyl (optionally substituted with cyano, hydroxy, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, COR⁵⁸, SO₂NR⁵⁸R⁵⁹, C(O)NR⁷⁵R⁷⁶, NR⁷⁴COR⁶⁵, NR⁷³SO₂R⁶⁶, NHC(O)NR⁶⁷R⁷², NR⁶⁸R⁶⁹, SO₂R⁷⁷, C(O)R⁷⁸, heterocyclyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ 20 cycloalkyl, phenyl, heterocyclyl, heteroaryl, OR⁷⁹, SR⁷⁹, CONR³⁹R⁴⁰, COR³⁹, NR³⁹R⁴⁰, (wherein R³⁹ and R⁴⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; R⁷⁹ is C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl), NR⁷⁰SO₂R⁷¹ or NR⁷⁰C(O)R⁷¹ 25 (wherein R⁷⁰, R⁷³ and R⁷⁴ are, independently, hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or C₃₋₆ cycloalkyl; and R⁷¹ is C₁₋₆ alkyl, C₃₋₇ cycloalkyl, aryl or heteroaryl); R¹³, R¹⁵ and R¹⁹ are, independently, hydrogen, C₁₋₆ alkyl or phenyl; R⁶ and R¹⁴ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl), phenyl or heteroaryl; R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹⁶, R¹⁷, R¹⁸, R²⁰, R²¹, R⁵⁸, R⁵⁹, R⁶⁷, R⁶⁸, R⁶⁹, R⁷², R⁷⁵ and 30 R⁷⁶ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, heterocyclyl, CONR⁶⁰R⁶¹, or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl; unless specified otherwise, the foregoing aryl, phenyl and heteroaryl moieties are optionally substituted with

halo, cyano, nitro, hydroxy, $S(O)_qR^{41}$, $NR^{42}R^{43}$, $SO_2NR^{44}R^{45}$, $CONR^{46}R^{47}$, $NR^{48}SO_2R^{49}$, $NR^{51}COR^{52}$, COR^{53} , CO_2R^{54} , $NR^{55}CONR^{56}R^{57}$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkoxy(C_{1-6})alkyl, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C_{1-4} alkyl or C_{1-4} alkoxy; R^{48} , R^{51} and R^{55} are, independently, hydrogen, C_{1-6} alkyl or phenyl; R^{41} , R^{49} , R^{66} are, independently, alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C_{1-4} alkyl or C_{1-4} alkoxy)), phenyl or heteroaryl; R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{47} , R^{52} , R^{53} , R^{54} , R^{56} , R^{57} , R^{60} , R^{61} and R^{65} are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C_{1-4} alkyl or C_{1-4} alkoxy)), phenyl or heteroaryl; the pairs of substituents: R^7 and R^8 , R^9 and R^{10} , R^{11} and R^{12} , R^{20} and R^{21} , R^{37} and R^{38} , R^{39} and R^{40} , R^{42} and R^{43} , R^{44} and R^{45} , R^{46} and R^{47} , R^{56} and R^{57} , R^{58} and R^{59} , R^{75} and R^{76} , R^{67} and R^{72} and R^{68} and R^{69} may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom; R^{77} and R^{78} are, independently, *N*-linked heterocyclyl; where for any of the foregoing heterocyclic groups having a ring $-N(H)-$ moiety, that $-N(H)-$ moiety may be optionally substituted by C_{1-4} alkyl (itself optionally substituted by hydroxy), $C(O)(C_{1-4}$ alkyl), $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl) $_2$ or $SO_2(C_{1-4}$ alkyl); m , p and q are, independently, 0, 1 or 2; a ring nitrogen and/or sulphur atom is optionally oxidised to form an *N*-oxide and/or an *S*-oxide; or a pharmaceutically acceptable salt thereof; provided that when R^{2a} and R^{2b} are both hydrogen and R^5 is hydrogen or methyl, then R^1 is not 2-phenylethyl.

In yet another aspect the present invention provides a compound of formula (Ib) wherein: R^{2a} , and R^{2b} are, independently, hydrogen, halo, cyano, nitro, hydroxy, SH , $S(O)_pR^6$, NR^7R^8 , $SO_2NR^9R^{10}$, $CONR^{11}R^{12}$, $NR^{13}SO_2R^{14}$, $NR^{15}COR^{16}$, COR^{17} , CO_2R^{18} , $NR^{19}CONR^{20}R^{21}$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkenyloxy, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkoxy(C_{1-6})alkyl or heterocyclyl, or phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy, wherein any of the foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C_{1-4} alkyl or C_{1-4} alkoxy; R^1 is C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-8} alkenyl or C_{3-8} alkynyl, each optionally substituted with one or more of: halo, hydroxy, cyano, nitro, C_{1-6} alkoxy (itself optionally substituted by heterocyclyl

or CONR⁶²R⁶³), C₃₋₇ cycloalkyl, NR²²R²³, C(O)R²⁴, NR²⁵SO₂R²⁶, NR²⁷C(O)R²⁸, SO₂NR²⁹R³⁰, CONR³¹R³², NR³³CONR³⁴R³⁵, S(O)_mR⁶⁴, heterocyclyl, heterocyclyloxy, aryl, aryloxy, heteroaryl or heteroaryloxy; R⁵ is hydrogen; R⁶⁴ is alkyl, cycloalkyl, aryl or heteroaryl; R¹³, R¹⁵, R¹⁹, R²⁵, R²⁷, R³³, are, independently, hydrogen, C₁₋₆ alkyl or phenyl; R⁶, R¹⁴ and R²⁶ are, 5 independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl), phenyl or heteroaryl; R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹⁶, R¹⁷, R¹⁸, R²⁰, R²¹, R²², R²³, R²⁴, R²⁸, R²⁹, R³⁰, R³¹, R³², R³⁴ and R³⁵ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, heterocyclyl, CONR⁶⁰R⁶¹, or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl; unless specified otherwise, the foregoing aryl, phenyl and heteroaryl 10 moieties are optionally substituted with halo, cyano, nitro, hydroxy, S(O)_qR⁴¹, NR⁴²R⁴³, SO₂NR⁴⁴R⁴⁵, CONR⁴⁶R⁴⁷, NR⁴⁸SO₂R⁴⁹, NR⁵¹COR⁵², COR⁵³, CO₂R⁵⁴, NR⁵⁵CONR⁵⁶R⁵⁷, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, 15 heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy; R⁴⁸, R⁵¹ and R⁵⁵ are, independently, hydrogen, C₁₋₆ alkyl or phenyl; R⁴¹ and R⁴⁹ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, 20 hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl; R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁵², R⁵³, R⁵⁴, R⁵⁶, R⁵⁷, R⁶⁰, R⁶¹, R⁶² and R⁶³ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl; the pairs 25 of substituents: R⁷ and R⁸, R⁹ and R¹⁰, R¹¹ and R¹², R²⁰ and R²¹, R²² and R²³, R²⁹ and R³⁰, R³¹ and R³², R³⁴ and R³⁵, R³⁷ and R³⁸, R⁴² and R⁴³, R⁴⁴ and R⁴⁵, R⁴⁶ and R⁴⁷ and R⁵⁶ and R⁵⁷ may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom; where for any of the foregoing heterocyclic groups having a ring -N(H)- moiety, that -N(H)- moiety may be optionally substituted by C₁₋₄ alkyl (itself optionally substituted by hydroxy), C(O)(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ or SO₂(C₁₋₄ alkyl); m, p and q are, independently, 0, 1 or 2; a ring nitrogen and/or sulphur atom is 30 optionally oxidised to form an N-oxide and/or an S-oxide; or a pharmaceutically acceptable salt thereof; provided that when R^{2a} and R^{2b} are both hydrogen then R¹ is not methyl, benzyl, C₃₋₄ alkylene substituted once by tetrahydropthalimide, 3-(4-fluorobenzoyl)propyl, (3,4-

dihydro-2H-1-benzopyran-2-yl)methyl or a 3-(2-oxo-3,6-dihydro-4-methyl-6-(3,4-difluorophenyl)-2H-pyrimidin-1-ylcarbonylamino)propyl; and provided that when R^{2a} is 5-fluoro and R^{2b} is hydrogen then R^1 is not 2-(3-(4-fluorophenyl)-5-aminothiazol-2-yl)ethyl.

In a further aspect the present invention provides a compound as hereinbefore defined

5 wherein R^{2a} and R^{2b} are, independently, hydrogen, halo, OH, CN, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂, $NHC(O)(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)C(O)(C₁₋₄ alkyl), $NHSO_2(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)SO₂(C₁₋₄ alkyl), SH, S(O)(C₁₋₄ alkyl), SO₂(C₁₋₄ alkyl), SO₂NH₂, SO₂NH(C₁₋₄ alkyl), SO₂N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₂₋₄ alkenyl, C₂₋₄ alkenyloxy, 10 C₂₋₄ alkynyl, C(O)(C₁₋₄ alkyl), SCF₃, SO₂CF₃, phenyl, heterocyclyl or heteroaryl; the phenyl and heteroaryl groups being optionally substituted as recited above.


In another aspect the present invention provides a compound as hereinbefore described wherein R^3 and R^4 and, if present R^{3a} and R^{4a} are all hydrogen.

In a further aspect the invention provides a compound as hereinbefore described

15 wherein R^1 is 2,6-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4-dimethoxy-6-hydroxybenzyl, 3-(4-dimethylaminophenyl)prop-2-enyl, (1-phenyl-2,5-dimethylpyrrol-3-yl)methyl, 2-phenylethyl, 3-phenylpropyl, 3-R/S-phenylbutyl, 3-cyano-3,3-diphenylpropyl, 3-cyano-3-phenylpropyl, 4-(*N*-methylbenzene-sulphonamido)-3-phenylbutyl, 4-(*N*-methylbenzamido)-3-phenylbutyl or 3,3-diphenylpropyl.

20 In a still further aspect the invention provides a compound as hereinbefore described wherein R^1 is 3-R/S-phenylbutyl, 3-cyano-3,3-diphenylpropyl, 3-cyano-3-phenylpropyl, 4-(*N*-methylbenzenesulphonamido)-3-phenylbutyl, 4-(*N*-methylbenzamido)-3-phenylbutyl or, preferably, 3,3-diphenylpropyl.


In another aspect the present invention provides a compound of formula (Ig):



wherein X-Y is N=CH or N=N; R¹ is (CH₂)_rCHR'R''; R^{2a} is hydrogen or halo (such as fluoro); R^{2b} is hydrogen, halo (such as fluoro or chloro), CF₃, cyano or C₁₋₄ alkyl (such as methyl); R^{2c} is hydrogen, halo (such as fluoro or chloro) or C₁₋₄ alkyl (such as methyl); R^{2d} is hydrogen or halo (such as chloro); r is 2 or 3; R' is phenyl optionally substituted by halo (such as chloro); and, R'' is C₁₋₄ alkyl (optionally mono-substituted with N(C₁₋₄ alkyl)SO₂phenyl) or phenyl.

5 In yet another aspect R⁵ is hydrogen or C₁₋₄ alkyl (for example methyl). The group R⁵ is particularly hydrogen.

In a further aspect the present invention provides a compound of formula (Ih):



10

wherein

R¹ is CR⁸⁰R⁸¹CR⁸²R⁸³R⁸⁴;

R⁸⁴ is OR⁸⁵, NR⁸⁶R⁸⁷ or CR⁸⁸R⁸⁹R⁹⁰;

R⁸⁰, R⁸¹, R⁸², R⁸³ and R⁸⁸ are, independently, hydrogen or C₁₋₄ alkyl (for example methyl);
15 R⁸⁵, R⁸⁷ and R⁸⁹ are phenyl or heteroaryl;

R⁸⁶ is hydrogen, C₁₋₄ alkyl, phenyl, heteroaryl, C(O)phenyl or C(O)heteroaryl;

R⁹⁰ is C₁₋₄ alkyl, phenyl, heteroaryl, heterocycl, phenoxy, heteroaryloxy, NHC(O)(C₁₋₆ alkyl), NHC(O)phenyl, NHC(O)heteroaryl, C₃₋₇ cycloalkyl, CH₂C(O)(C₁₋₆ alkyl), NHC(O)NH(C₁₋₆ alkyl) or NHC(O)O(C₁₋₆ alkyl);

20 R^{2a}, R^{2b}, R^{2c} and R^{2d} are, independently, hydrogen, halogen, cyano, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂; and,

R⁵ is hydrogen or C₁₋₄ alkyl (for example methyl), {R⁵ is especially hydrogen};

wherein the foregoing phenyl and heteroaryl groups and moieties are optionally substituted by halogen (especially chlorine or fluorine) or CF₃.

25 In another aspect the present invention provides a compound as hereinbefore defined wherein R¹ is CR⁸⁰R⁸¹CR⁸²R⁸³R⁸⁴; R⁸⁴ is OR⁸⁵, NR⁸⁶R⁸⁷ or CR⁸⁸R⁸⁹R⁹⁰; R⁸⁰, R⁸¹, R⁸², R⁸³ and


R⁸⁸ are, independently, hydrogen or C₁₋₄ alkyl (for example methyl); R⁸⁵, R⁸⁷ and R⁸⁹ are phenyl or heteroaryl; R⁸⁶ is hydrogen, C₁₋₄ alkyl, phenyl, heteroaryl, C(O)phenyl or C(O)heteroaryl; and R⁹⁰ is C₁₋₄ alkyl, phenyl, heteroaryl, heterocyclyl, phenoxy, heteroaryloxy, NHC(O)(C₁₋₆ alkyl), NHC(O)phenyl, NHC(O)heteroaryl, C₃₋₇ cycloalkyl, 5 CH₂C(O)(C₁₋₆ alkyl), NHC(O)NH(C₁₋₆ alkyl), NHC(O)O(C₁₋₆ alkyl); wherein the foregoing phenyl and heteroaryl groups and moieties are optionally substituted by halogen (especially chlorine or fluorine) or CF₃.

In yet another aspect the present invention provides a compound of formula (Ih) wherein R⁸⁴ is CR⁸⁸R⁸⁹R⁹⁰.

10 In yet another aspect three of R^{2a}, R^{2b}, R^{2c} and R^{2d} are hydrogen and the other is S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂. In a further aspect R^{2a}, R^{2c} and R^{2d} are all hydrogen and R^{2b} is S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂ {especially R^{2b} is S(O)₂(C₁₋₄ alkyl), for example S(O)₂CH₃}.

15 In a further aspect the present invention provides a compound of formula (I) or (Ia) wherein J, L and M are as defined above; K is CR^{2b}; and R^{2b} is S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂ {especially R^{2b} is S(O)₂(C₁₋₄ alkyl), for example S(O)₂CH₃}.

In a still further aspect the present invention provides a compound of formula (Ij):




20 wherein R⁸⁹ and R⁹⁰ are as defined above.

When R¹ is 3-phenyl-butyl it is preferably in the form of the S-isomer.

Examples of compounds of the invention are provided in the Examples below and in the Tables hereunder.

TABLE I

25 Table I concerns compounds of formula (Ij):



wherein R⁸⁹ and R⁹⁰ are as defined in the table below.


Compound No.	R ⁸⁹	R ⁹⁰	Comment
1	Phenyl	Phenyl	
2	Phenyl	Methyl	
3	Phenyl	Methyl	S-isomer
4	Phenyl	Pyridin-2-yl	
5	Phenyl	Pyrimidin-2-yl	
6	4-fluoro-phenyl	Pyridin-2-yl	
7	4-CF ₃ -phenyl	Pyridin-2-yl	
8	3-fluoro-phenyl	Pyridin-2-yl	
9	3-fluoro-phenyl	Pyrazin-2-yl	
10	3-fluoro-phenyl	NHC(O)phenyl	
11	3-fluoro-phenyl	NHC(O)thien-3-yl	
12	4-CF ₃ -phenyl	NHC(O)CH(CH ₃) ₂	
13	4-CF ₃ -phenyl	NHC(O)NHCH(CH ₃) ₂	
14	Phenyl	4-fluoro-phenyl	
15	3-fluoro-phenyl	Thien-3-yl	
16	3-fluoro-phenyl	Pyridin-3-yl	
17	Phenyl	Pyridin-2-yloxy	
18	Phenyl	4-CF ₃ -phenyl	
19	Pyrimidin-4-yl	3-chloro-phenyl	
20	3-fluoro-phenyl	NHC(O)phenyl	
21	4-CF ₃ -phenyl	NHC(O)thien-2-yl	
22	4-CF ₃ -phenyl	CH ₂ C(O)CH(CH ₃) ₂	
23	Phenyl	cyclobutyl	

24	Phenyl	phenoxy	
25	4-CF ₃ -phenyl	methyl	
26	4-CF ₃ -phenyl	Methyl	S-isomer
27	3-fluoro-phenyl	NHC(O)OCH(CH ₃) ₂	

The compounds of the invention can be prepared by adaptation of methods disclosed in the chemical art. For example compounds of formula (Ib), (Ic), (Ig), (Ih) and (Ik) can be prepared following the reaction sequences shown in Schemes 1 and 2 in which the reagents are as follows:


- i. starting material can be prepared by adaptation of route described in EP309422; a fluoronitrobenzene or a chloronitrobenzene
- ii. Raney nickel hydrogenation
- iii. an alkylorthoformate
- iv. hydrogenation (for example hydrogen in the presence of palladium of carbon catalyst)
- v. reductive amination of aldehyde or alkylation with R”L (where L is a leaving group)
- vi. Boc chloride or anhydride
- vii. hydrogenation (for example hydrogen in the presence of palladium of carbon catalyst)
- viii. reductive amination of aldehyde or alkylation with R”L (where L is a leaving group)
- ix. trifluoroacetic acid
- x. a fluoronitrobenzene or a chloronitrobenzene
- xi. Raney nickel hydrogenation
- xii. an alkylorthoformate

Alternatively, compounds of formula (I), where A is piperidine, can be made by first reducing a compound of formula (II):




and then cyclising the product so formed. (For example, cyclising in the presence of NaNO_2 and dilute hydrochloric acid as 0-5°C to produce a triazole ring; or cyclising in the presence of $\text{R}^5\text{CO}_2\text{H}$ in refluxing toluene to produce an imidazole ring.)

A compound of formula (II) can be prepared by coupling a compound of formula (III):




wherein LG is a leaving group (such as chlorine), with a compound of formula (IV):




in the presence of a base. Compounds of formula (III) can be made by nitration of the respective chloroheteroaryl or respective chloroheteroaryl *N*-oxide (followed by reduction to remove the *N*-oxide); or by chlorination of an oxo-nitro-heteroaryl (such as 3-nitropyridin-4-one).

10 Alternatively, compounds of formula (I), where A is piperidine, can be prepared by coupling a compound of formula (V):




15 with a compound of formula (VI)




wherein LG is a leaving group such as chlorine, tosyl or methylsulphonyl, in the presence of a base.

20 Compounds of formula (If) can be prepared by alkylation or reductive amination of a compound of formula (VII):



for example alkylation with a compound of formula (IX):



Alternatively compounds of formula (I) can be prepared by preparing compounds of formula (VIII), for example as shown in Scheme 3, and then cyclising the compound of formula (VIII) as hereinbefore described.

Compounds of formula (I) wherein A is other than piperidine can be prepared by adaptation of literature methods or by adaptation of methodologies described above.

In another aspect the present invention provides processes for the preparation of compounds of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij).

Many of the intermediates defined herein are novel and these are provided as a further feature of the invention.

By virtue of them being modulators (such as agonists, partial agonists, inverse agonists or antagonists) of the CCR5 receptor the compounds of the present invention are of value in the prevention or treatment of inflammatory and immunoregulatory disorders and diseases including asthma, allergic diseases and transplant rejection as well as autoimmune pathologies such as rheumatoid arthritis, atherosclerosis, psoriasis, systemic lupus erythematosus (SLE), ulcerative colitis, multiple sclerosis, glomerulonephritis, together with chronic obstructive pulmonary disease (COPD, including pulmonary fibrosis) and cerebral malaria. The compounds of the present invention are also of value in inhibiting the entry of viruses (such as human immunodeficiency virus (HIV)) into target cells and, therefore, are of value in the prevention of infection by viruses (such as HIV), the treatment of infection by viruses (such as HIV) and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS).

According to a further feature of the invention there is provided a compound of the formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.

According to a further feature of the present invention there is provided a method for 5 modulating a CCR5 receptor in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

The invention also provides a compound of the formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, for use as a medicament.

10 In another aspect the present invention provides the use of a compound of the formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in modulating a CCR5 receptor in a warm blooded animal, such as man.

15 The invention further provides the use of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma, transplant rejection, rheumatoid arthritis, atherosclerosis, psoriasis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, glomerulonephritis, chronic obstructive pulmonary disease, cerebral malaria, human immunodeficiency virus infection and acquired immune deficiency syndrome 20 in a warm blooded animal, such as man.

The invention further provides the use of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis in a warm blooded animal, such as man.

25 The present invention further provides a method of treating a CCR5 mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof.

30 The present invention further provides a method of treating rheumatoid arthritis in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof, for the therapeutic treatment of mammals including humans, in particular modulating a CCR5 receptor, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

5 Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

10 The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or 15 suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 10mg and 1g of the compound of this invention.

20 In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.1mgkg^{-1} to 100mgkg^{-1} of the compound, preferably in the range of 0.5mgkg^{-1} to 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus 25 injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

30 The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically-acceptable salt thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

5

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

(e)

<u>Injection I</u>	(50 mg/ml)
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β -cyclodextrin may be used to aid formulation.

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

(i) temperatures are given in degrees Celsius ($^{\circ}\text{C}$); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 $^{\circ}\text{C}$;

(ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60 $^{\circ}\text{C}$;

(iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond ElutTM" column is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI". Where an "IsoluteTM SCX column" is referred to, this means a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK.

(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;

(v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;

(vi) when given, ^1H NMR data is quoted and is in the form of delta values for major

diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an

internal standard, determined at 300MHz using perdeuterio DMSO (CD_3SOCD_3) as the solvent unless otherwise stated; coupling constants (J) are given in Hz:

(vii) chemical symbols have their usual meanings; SI units and symbols are used;

(viii) solvent ratios are given in percentage by volume;

5 (ix) mass spectra (MS) were run using standard mass spectrometry techniques; where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;

(x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry

10 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;

15 and

(xi) the following abbreviations are used:

DMSO dimethyl sulphoxide;

DMF N,N -dimethylformamide;

DCM dichloromethane;

20 EEDQ 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline;

EtOH ethanol;

EtOAc ethyl acetate;


M.pt. melting point

25 HATU O-(7-Azabenzotriazol-1-yl)- N,N,N',N' -tetramethyluronium hexafluorophosphate; and

NMP N -methylpyrrolidinone;

Example 1


1-[1-(3R/S-Phenylbutyl)-piperidin-4-yl]-benzimidazole



30 3-(R/S)-Phenylbutyraldehyde (0.25ml, 1.6mmol) was added to a solution of 1-(1*H*-piperidin-4-yl)benzimidazole (Method A) (300mg, 1.5mmol) in methanol (10ml) and acetic

acid (1ml) was then added. After 1 hour sodium triacetoxyborohydride (474mg, 2.2mmol) was added portionwise over 15mins and the reaction was left to stir for 70h. Water (5ml) was added to the mixture and the methanol was removed *in vacuo*. The solution was diluted with water (60ml), and partitioned with EtOAc (3 x 70ml). The organic fractions were combined and washed with water (30ml), dried (MgSO_4) and concentrated to give a pale yellow oil. The residue was chromatographed on silica (MPLC) eluting with EtOAc followed by 4% EtOH/EtOAc to give the title compound as a gum (350mg, 1.05mmol); NMR: 1.2 (d, 3H), 1.7 (q, 2H), 2.0 (m, 6H), 2.2 (m, 2H), 2.8 (m, 1H), 2.95 (m, 2H), 4.3 (m, 1H), 7.2 (m, 7H), 7.6 (t, 2H) and 8.3 (s, 1H); MS: 334.


10 **Example 2**



1-[1-(3,3-Diphenylpropyl)-piperidin-4-yl]benzimidazole

3,3-Diphenylpropyl bromide (1.36 g, 5 mmol) was added dropwise to a suspension of potassium carbonate (688 mg, 5 mmol), *tetra*-butylammonium iodide (10 mg) and 1-(1*H*-piperidin-4-yl)benzimidazole (Method A) (500 mg, 2.49 mmol) in DMF (15 ml). After 15h the mixture was poured into 50% brine (30 ml) and extracted with EtOAc (2 x 50 ml). The combined organics were washed with water (25 ml), dried (MgSO_4), concentrated and chromatographed on silica (MPLC) eluting with DCM / EtOAc (1:1) followed by 4% EtOH/EtOAc to give the title compound as a white solid (550 mg, 1.4 mmol); M. pt.. 156-157°C; NMR: 2.0 (m, 6H), 2.25 (m, 4H), 2.95 (m, 2H), 4.0 (t, 1H), 4.3 (m, 1H), 7.2 (m, 12H) 7.6 (t, 2H) and 8.3 (s, 1H); MS: 396.


Example 3



1-[1-(3-{3,4-Dichlorophenyl}-4-{N-methylbenzenesulphonamide}butyl)-piperidin-4-yl]-benzimidazole

The procedure shown in Example 2 was followed except that 1-bromo-3-(3,4-dichlorophenyl)-4-(N-methylbenzenesulphonamide)butane (Method G) (114 mg, 0.25 mmol), 5 1-(1*H*-piperidin-4-yl)benzimidazole (Method A) (50 mg, 0.23 mmol), potassium carbonate (127 mg, 0.92 mmol) and DMF (7 ml) were used to give the title compound as a solid (20 mg, 0.035 mmol); MS: 571.

Example 4



10 5-Fluoro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]benzimidazole

A solution of 2-amino-4-fluoro-1-*N*-(1-(3R/S-phenylbutyl)-piperidin-4-yl)aniline (prepared as described below) (40 mg, 0.12 mmol), trimethyl orthoformate (0.5 ml, 4.8 mmol) and *para*-toluenesulphonic acid monohydrate (5 mg, 0.03 mmol) was stirred at 100°C. After 2h the mixture was cooled and water (2 ml) was added. The solution was partitioned with 15 DCM (2 x 3 ml) then the organics were combined, dried (MgSO_4) and concentrated to give the title compound as an oil that did not need further purification (27 mg, 0.08 mmol); NMR: 1.25 (d, 3H), 1.75 (m, 2H), 2.2 (m, 6H), 2.9 (m, 2H), 4.4 (m, 1H), 7.2 (m, 6H), 7.45 (m, 1H), 7.65 (m, 1H) and 8.4 (s, 1H); MS: 352.

2-Amino-4-fluoro-1-*N*-(1-(3R/S-phenylbutyl)-piperidin-4-yl)aniline

20 A mixture of 4-amino-1-(3R/S-phenylbutyl)piperidine (Method E) (500 mg, 1.45 mmol), 2,5-difluoronitrobenzene (0.18 ml, 1.6 mmol) and potassium carbonate (600 mg, 4.4 mmol) in DMSO (5 ml) was heated at 90°C. After 15h the mixture was poured onto ice and extracted with EtOAc (3 x 50ml). The combined organics were dried (MgSO_4), concentrated and purified by Bond Elut chromatography (eluting with DCM followed by 50% EtOAc/ 25 DCM) to give 4-fluoro-2-nitro-1-*N*-(1-(3R/S-phenylbutyl)-piperidin-4-yl)aniline as a gum (280 mg, 0.75 mmol); NMR: 1.2 (d, 3H), 1.5 (q, 2H), 1.7 (q, 2H), 1.9 (m, 2H), 2.1 (m, 4H), 2.7 (m, 3H), 3.6 (m, 1H), 7.2 (m, 5H), 7.5 (m, 1H) and 7.8 (m, 2H); MS: 372.

To a stirred solution of suspension of 4-fluoro-2-nitro-1-*N*-(1-(3R/S-phenylbutyl)-piperidin-4-yl)aniline (275 mg, 0.74 mmol) in methanol (5 ml) was added concentrated HCl

(1 ml) followed by stannous chloride dihydrate (300 mg, 1.3 mmol) and the mixture was heated to 100°C. After 2h, further stannous chloride dihydrate (100 mg), methanol (2 ml) and concentrated HCl (1 ml) were added and the mixture heated to 70°C. After 15h, further stannous chloride dihydrate (50 mg) and methanol (2 ml) were added and the mixture continued to be heated at 70°C. After 24h the reaction mixture was concentrated and suspended in water (50 ml) and potassium carbonate was added to neutralise the solution. The solution was extracted with DCM (3 x 70 ml) and the combined extracts were dried (MgSO₄), concentrated and purified by Bond Elut chromatography (eluting with EtOAc followed by 4% EtOH/ EtOAc and 1% isopropylamine in 4% EtOH/ EtOAc) to give 2-amino-4-fluoro-1-N-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline as an oil (210 mg, 0.62 mmol); NMR: 1.2 (d, 3H), 1.35 (q, 2H), 1.7 (m, 2H), 1.9 (m, 4H), 2.1 (m, 2H), 2.7 (m, 3H), 3.0 (m, 3H), 3.9 (d, 1H), 4.8 (br s, 2H), 6.1 (m, 1H), 6.3 (m, 2H) and 7.2 (m, 5H); MS: 342.

Example 5-14

The procedure described in Example 4 was repeated using the appropriate starting material (shown below) to replace the 2,5-difluoronitrobenzene to obtain the compounds described in the following table.


Example No.	Starting Material	Final Product	MS (MH ⁺)
5	2,6-Difluoro-nitrobenzene	4-Fluoro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	352
6	2,4-Difluoro-nitrobenzene	6-Fluoro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	352

7	2-Fluoro-4-methyl-nitrobenzene	6-Methyl-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	348
8	2-Fluoro-5-methylnitrobenzene	5-Methyl-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	348
9	2,4,5-Trichloro-nitrobenzene	5,6-Dichloro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	402
10	2,4-Dichloro-nitrobenzene	6-Chloro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	368
11	2,3,4-Trichloro-nitrobenzene	6,7-Dichloro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	402

12	2-Chloro-5-cyano-nitrobenzene	5-Cyano-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	359
13	2,5-Dichloro-nitrobenzene	5-Chloro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole	368
14	2,6-Dichloro-3-nitropyridine	6-Chloro-7-aza-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole [‡]	369

[‡] This final product was purified on a Bond ElutTM eluting with DCM, then 5% EtOH/DCM and finally 10% EtOH/DCM.

5 **Example 15**




1-[1-(3,3-Diphenylpropyl)-piperidin-4-yl]benzotriazole

The procedure shown in Example 2 was followed except that 3,3-diphenylpropyl bromide (570 mg, 2.1 mmol), 4-benzotriazol-1-yl-piperidine hydrochloride (250 mg, 1.05 mmol), potassium carbonate (580 mg, 4.2 mmol) and DMF (5 ml) were used to give the title

compound as a gum (170 mg, 0.43 mmol); NMR: 2.2 (m, 9H), 3.0 (m, 2H), 4.0 (m, 2H), 4.8 (m, 1H), 7.1 (m, 2H), 7.3 (m, 9H), 7.5 (t, 1H), 7.8 (d, 1H) and 8.05 (d, 1H); MS: 397.


Example 16



5 1-[1-(3,3-Diphenylpropyl)-piperidin-4-yl]-5-trifluoromethylbenzotriazole

The procedure shown in Example 2 was followed except that 3,3-diphenylpropyl bromide (570 mg, 2.1 mmol), 4-(5-trifluoromethyl)benzotriazol-1-yl-piperidine hydrochloride (321 mg, 1.05 mmol), potassium carbonate (580 mg, 4.2 mmol) and DMF (5 ml) were used to give the title compound as a gum (320 mg, 0.69 mmol); NMR: 2.2 (m, 9H), 3.0 (d, 2H), 4.0 (m, 2H), 4.9 (m, 1H), 7.1 (m, 2H), 7.3 (m, 8H), 7.8 (d, 1H), 8.15 (d, 1H) and 8.5 (d, 1H); MS: 465.


Example 17



1-[1-(3R/S-Phenylbutyl)-piperidin-4-yl]benzotriazole


15 The procedure shown in Example 1 was followed except that 3-(R/S)-phenylbutyraldehyde (0.18 ml, 1.2 mmol), 4-benzotriazol-1-yl-piperidine hydrochloride (250 mg, 1.1 mmol), sodium triacetoxyborohydride (334 mg, 1.6 mmol) and acetic acid (0.5 ml) in methanol (5 ml) were used to give the title compound as a white solid (210 mg, 0.63 mmol); NMR: 1.2 (d, 3H), 1.8 (m, 2H), 2.2 (m, 7H), 2.9 (m, 3H), 4.9 (m, 1H), 7.2 (m, 5H), 7.4 (t, 1H), 7.5 (t, 1H), 7.9 (d, 1H) and 8.1 (d, 1H); MS: 335.

Example 18




1-[1-(3R/S-Phenylbutyl)-piperidin-4-yl]-5-trifluoromethylbenzotriazole

The procedure shown in Example 1 was followed except that 3-(R/S)-phenylbutyraldehyde (0.18 ml, 1.2 mmol), 4-(5-trifluoromethyl)benzotriazol-1-yl-piperidine hydrochloride (325 mg, 1.1 mmol), sodium triacetoxyborohydride (334 mg, 1.6 mmol) and 5 acetic acid (0.5 ml) in methanol (5 ml) were used to give the title compound as a gum (180 mg, 0.48 mmol); NMR: 1.2 (d, 3H), 1.8 (m, 2H), 2.2 (m, 6H), 2.8 (m, 2H), 3.0 (m, 2H), 4.95 (m, 1H), 7.2 (m, 5H), 7.8 (d, 1H), 8.15 (d, 1H) and 8.5 (s, 1H); MS: 403.

Example 1910 1-[1-(3-Cyano-3,3-diphenylpropyl)-piperidin-4-yl]benzimidazole


4-Bromo-2,2-diphenylbutyronitrile (507mg, 1.7 mmol) was added dropwise to a suspension of potassium carbonate (234 mg, 1.7 mmol), *tetra*-butylammonium iodide (10 mg) and 1-(1*H*-piperidin-4-yl)benzimidazole (Method A) (170 mg, 0.85 mmol) in DMF (10 ml) and the reaction mixture was heated to 90°C. After 15h the mixture was poured into water (30 ml) and extracted with EtOAc (3 x 60 ml). The combined organics were dried (MgSO₄), concentrated and chromatographed on silica (medium pressure liquid chromatography, MPLC) eluting with DCM followed by 5% EtOH/ DCM to give the title compound as a pale yellow solid (70 mg, 0.17 mmol); M. pt., 172-173°C; NMR: 2.0 (m, 6H), 2.4 (m, 2H), 2.7 (m, 2H), 3.0 (d, 2H), 4.3 (m, 1H), 7.2 (m, 2H), 7.4 (m, 10H), 7.6 (m, 2H) and 8.2 (s, 1H); MS: 20 422.

Example 202-Methyl-1-[1-(3R/S-Phenylbutyl)-piperidin-4-yl]-benzimidazole

To a solution of 2-acetamido-1-*N*-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline 25 (Method P) (55 mg, 0.15mmol) in chloroform (5ml) was added phosphorous pentachloride

(62 mg, 0.3mmol) and the mixture refluxed. After 3h the reaction mixture was cooled and water (15ml) was added carefully followed by potassium carbonate until pH>9. The mixture was then extracted with DCM (2x20ml) and the combined organics dried (MgSO_4), concentrated and chromatographed on silica (MPLC) eluting with DCM followed by 2.5% EtOH/ DCM and finally 5% EtOH/ DCM to give the title compound as a pale yellow oil (40 mg, 1.15 mmol); NMR: 1.2 (d, 3H), 1.8 (m, 4H), 2.05 (m, 2H), 2.3 (m, 4H), 2.6 (s, 3H), 2.75 (m, 1H), 2.9 (m, 2H), 4.2 (m, 1H), 7.1 (m, 3H), 7.3 (m, 4H) and 7.5 (m, 2H); MS: 348.

Example 21



10 5-Methanesulphonyl-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]-benzimidazole

A solution of 2-amino-4-methanesulphonyl-1-N-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline (prepared as described below) (390 mg, 0.97 mmol), trimethyl orthoformate (3 ml) and *para*-toluenesulphonic acid monohydrate (15 mg, 0.09 mmol) was stirred at 100°C. After 2h the mixture was cooled and water (10 ml) was added. The solution was partitioned with DCM (3 x 30 ml) then the organics were combined, dried (MgSO_4) and concentrated to give an oil that was purified first by MPLC eluting with DCM followed by 2.5% EtOH/ DCM and then by chromatography (20g silica Bond ElutTM) eluting with DCM followed by 1.5% EtOH/ DCM and finally 3% EtOH/DCM to give the title compound as an orange oil (140 mg, 0.34 mmol); NMR: 1.2 (d, 3H), 1.7 (m, 2H), 2.1 (m, 8H), 2.8 (m, 1H), 2.9 (m, 2H), 3.2 (s, 3H), 4.4 (m, 1H), 7.2 (m, 5H), 7.8 (d, 1H), 7.9 (d, 1H), 8.2 (s, 1H) and 8.6 (s, 1H); MS: 412.

20 2-Amino-4-methanesulphonyl-1-N-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline


A mixture of 4-amino-1-(3R/S-phenylbutyl)piperidine di-trifluoroacetate salt (Method E) (1.15g, 2.5 mmol), 2-fluoro,5-methanesulphonylnitrobenzene (603 mg, 2.75 mmol) and potassium carbonate (1.04 g, 7.5 mmol) in DMSO (10 ml) was heated at 90°C. After 3h the mixture was poured onto ice and extracted with EtOAc (3 x 100ml). The combined organics were dried (MgSO_4), concentrated and purified by Bond Elut chromatography (eluting with DCM followed by 25% EtOAc/ DCM, 50% EtOAc/DCM, 75% EtOAc/DCM and finally EtOAc) to give 4-methanesulphonyl-2-nitro-1-N-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline as a pale yellow oil (790 mg, 1.8 mmol); NMR: 1.2 (d, 3H), 1.6 (m, 4H), 1.9 (m, 2H), 2.1 (m,

4H), 2.7 (m, 3H), 3.2 (s, 3H), 3.7 (m, 1H), 7.2 (m, 5H), 7.9 (d, 1H), 8.2 (d, 1H) and 8.5 (m, 1H); MS: 432.

To a stirred solution of suspension of 4-methanesulphonyl-2-nitro-1-*N*-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline (780 mg, 1.81 mmol) in methanol (13 ml) was added 5 concentrated HCl (2.5 ml) followed by stannous chloride dihydrate (1.63 g, 7.2 mmol) and the mixture was heated to 100°C. After 2h the reaction mixture was concentrated and suspended in water (100 ml) and potassium carbonate was added to basify the solution. The solution was extracted with DCM (3 x 150 ml) and the combined extracts were dried (MgSO₄), concentrated and purified by Bond Elut chromatography (eluting with EtOAc followed by 10 4% EtOH/ EtOAc and 1% isopropylamine in 4% EtOH/ EtOAc) to give the title compound as a light brown oil (400 mg, 1 mmol); NMR: 1.2 (m, 3H), 1.4 (m, 2H), 1.7 (m, 2H), 1.9 (m, 4H), 2.1 (m, 2H), 2.8 (m, 3H), 2.95 (s, 3H), 5.0 (m, 3H), 5.75 (s, 1H), 6.5 (d, 1H), 6.95 (m, 2H) and 7.2 (m, 5H); MS: 402.

Example 22

Chiral



15

5-Methanesulphonyl-1-[1-(3-S-phenylbutyl)-piperidin-4-yl]-benzimidazole

A solution of 2-amino-4-methanesulphonyl-1-*N*-[1-(3-S-phenylbutyl)-piperidin-4-yl]aniline (prepared as described below) (440 mg, 1.1 mmol), trimethyl orthoformate (3 ml) and *para*-toluenesulphonic acid monohydrate (20 mg, 0.11 mmol) was stirred at 100°C. After 20 15h the mixture was cooled and water (10 ml) was added. The solution was partitioned with EtOAc (3 x 40 ml) then the organics were combined, dried (MgSO₄) and concentrated to give the title compound as an orange oil (430 mg, 1.05 mmol); NMR: 1.2 (d, 3H), 1.7 (m, 2H), 2.1 (m, 8H), 2.8 (m, 1H), 3.0 (m, 2H), 3.2 (s, 3H), 4.45 (br s, 1H), 7.2 (m, 5H), 7.75 (d, 1H), 7.9 (d, 1H), 8.2 (s, 1H) and 8.6 (s, 1H); MS: 412.


25 2-Amino-4-methanesulphonyl-1-*N*-[1-(3-S-phenylbutyl)-piperidin-4-yl]aniline

A mixture of 4-amino-1-*N*-(3-S-phenylbutyl)piperidine (Method M) (581 mg, 2.5 mmol), 2-fluoro-5-methanesulphonylnitrobenzene (603 mg, 2.75 mmol) and potassium carbonate (1.04 g, 7.5 mmol) in DMSO (10 ml) was heated at 90°C. After 3h the mixture was

5 poured onto ice and filtered off; the yellow solid was washed with water and dried to give 4-methanesulphonyl-2-nitro-1-*N*-[1-(3-*S*-phenylbutyl)-piperidin-4-yl]aniline as a yellow waxy oil (1.06 g, 2.5 mmol); NMR: 1.2 (d, 3H), 1.6 (m, 4H), 1.9 (m, 2H), 2.1 (m, 4H), 2.7 (m, 3H), 3.2 (s, 3H), 3.7 (m, 1H), 7.2 (m, 5H), 7.9 (m, 1H), 8.2 (m, 1H) and 8.5 (s, 1H); MS: 432.

10 To a stirred solution of 4-methanesulphonyl-2-nitro-1-*N*-[1-(3-*S*-phenylbutyl)-piperidin-4-yl]aniline (1.05 g, 2.44 mmol) in methanol (17 ml) was added concentrated HCl (3 ml) followed by stannous chloride dihydrate (2.2 g, 9.8 mmol) and the mixture was heated to 100°C. After 2h the reaction mixture was concentrated and suspended in water (100 ml) and potassium carbonate was added to basify the solution. The solution was extracted with DCM (3 x 150 ml) and the combined extracts were dried (MgSO_4), concentrated and purified by Bond Elut chromatography (eluting with EtOAc followed by 4% EtOH/ EtOAc and 1% isopropylamine in 4% EtOH/ EtOAc) to give the title compound as a light red oil (880 mg, 2.2 mmol); NMR: 1.2 (d, 3H), 1.4 (m, 2H), 1.7 (m, 2H), 1.9 (m, 4H), 2.1 (m, 2H), 2.7 (m, 3H), 2.95 (s, 3H), 5.0 (m, 3H), 6.5 (m, 1H), 6.95 (m, 2H) and 7.2 (m, 5H); MS: 402.

15 **Example 23**



5-Methanesulphonyl-1-[1-(3,3-diphenylpropyl)-piperidin-4-yl]-benzimidazole

20 A solution of 2-amino-4-methanesulphonyl-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (prepared as described below) (50 mg, 0.1mmol), trimethyl orthoformate (0.7 ml) and *para*-toluenesulphonic acid monohydrate (2 mg, 0.11 mmol) was stirred at 100°C. After 2.5h the mixture was cooled and water (10 ml) was added. The solution was partitioned with EtOAc (2 x 40 ml) then the organics were combined, dried (MgSO_4) and concentrated to give the title compound as an oil (47 mg, 0.1 mmol); MS: 474.


2-Amino-4-methanesulphonyl-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline

25 A mixture of 4-amino-1-*N*-(3,3-diphenylpropyl)piperidine di-trifluoroacetate (Method I) (500mg, 0.96 mmol), 2-fluoro-5-methanesulphonylnitrobenzene (380 mg, 1.47 mmol) and potassium carbonate (700 mg, 5.05 mmol) in DMSO (4 ml) was heated at 90°C. After 15h the mixture was poured onto water and extracted with EtOAc (2x30ml). The organics were

combined, washed with brine, dried (MgSO_4), concentrated and purified by Bond ElutTM chromatography to give 4-methanesulphonyl-2-nitro-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline as an oil (200 mg, 0.4 mmol); MS: 494.

To a stirred solution of 4-methanesulphonyl-2-nitro-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (200 mg, 0.4 mmol) in methanol (4 ml) was added concentrated HCl (1 ml) followed by stannous chloride dihydrate (620 mg) and the mixture was heated to 95°C. After 3h the reaction mixture was concentrated and suspended in water (100 ml) and potassium carbonate was added to basify the solution. The solution was extracted with EtOAc (150 ml) and the emulsion left to separate. The mixture was then filtered through CeliteTM, separated, dried (MgSO_4), concentrated and purified by Bond ElutTM chromatography (using 1% to 7.5% EtOH in DCM) to give the title compound as an oil (50 mg, 0.11 mmol); MS: 464.

Example 24



15 5-Cyano-1-[1-(3,3-diphenylpropyl)-piperidin-4-yl]-benzimidazole

A solution of 2-amino-4-cyano-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (prepared as described below) (60 mg, 0.15 mmol), trimethyl orthoformate (0.7 ml) and *para*-toluenesulphonic acid monohydrate (2 mg, 0.11 mmol) was stirred at 100°C. After 2.5h the mixture was cooled and water (10 ml) was added. The solution was partitioned with EtOAc (2 x 40 ml) then the organics were combined, dried (MgSO_4) and concentrated to give the title compound as an oil (58 mg, 0.15 mmol); MS: 421.


2-Amino-4-cyano-1-*N*-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline

A mixture of 4-amino-1-(3,3-diphenylpropyl)piperidine di-trifluoroacetate (Method I) (500 mg, 0.96 mmol), 2-chloro,3-nitrobenzonitrile (373 mg, 2.04 mmol) and potassium carbonate (700 mg, 5.05 mmol) in DMSO (4 ml) was heated at 90°C. After 15h the mixture was poured onto water and extracted with EtOAc (2x30ml). The organics were combined, washed with brine, dried (MgSO_4), concentrated and purified by Bond ElutTM chromatography

to give 4-cyano-2-nitro-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline as an oil (300 mg, 0.68 mmol); MS: 442.

To a stirred solution of 4-cyano-2-nitro-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (300 mg, 0.68 mmol) in methanol (4 ml) was added concentrated HCl (1 ml) followed by stannous chloride dihydrate (620 mg) and the mixture was heated to 95°C. After 3h the reaction mixture was concentrated and suspended in water (100 ml) and potassium carbonate was added to basify the solution. The solution was extracted with EtOAc (150 ml) and the emulsion left to separate. The mixture was then filtered through Celite™, separated, dried (MgSO_4), concentrated and purified by Bond Elut™ chromatography (using 1% to 7.5% EtOH in DCM) to give the title compound as an oil (60mg, 0.15 mmol); MS: 411.

Example 25



7-Aza-1-[1-(3,3-diphenylpropyl)-piperidin-4-yl]-benzimidazole


A solution of 2-amino-5-aza-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (prepared as described below) (35 mg, 0.09mmol), trimethyl orthoformate (0.7 ml) and *para*-toluenesulphonic acid monohydrate (2 mg, 0.11 mmol) was stirred at 100°C. After 2.5h the mixture was cooled and water (10 ml) was added. The solution was partitioned with EtOAc (2 x 40 ml) then the organics were combined, dried (MgSO_4) and concentrated to give the title compound as an oil (21 mg 0.05 mmol); MS: 397.

2-Amino-6-aza-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline

A mixture of 4-amino-1-(3,3-diphenylpropyl)piperidine di-trifluoroacetate (Method I) (500mg, 0.96 mmol), 2-chloro-3-nitropyridine (323 mg, 2.04 mmol) and potassium carbonate (700 mg, 5.05 mmol) in DMSO (4 ml) was heated at 90°C. After 15h the mixture was poured onto water and extracted with EtOAc (2x30ml). The organics were combined, washed with brine, dried (MgSO_4), concentrated and purified by Bond Elut™ chromatography to give 6-aza-2-nitro-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline the as an oil (350 mg, 0.84 mmol); MS: 417.

To a stirred solution of 6-aza-2-nitro-1-N-[1-(3,3-diphenylpropyl)-piperidin-4-yl]aniline (350 mg, 0.84 mmol) in methanol (4 ml) was added concentrated HCl (1 ml) followed by stannous chloride dihydrate (620 mg) and the mixture was heated to 95°C. After 3h the reaction mixture was concentrated and suspended in water (100 ml) and potassium 5 carbonate was added to basify the solution. The solution was extracted with EtOAc (150 ml) and the emulsion left to separate. The mixture was then filtered through Celite™, separated, dried (MgSO₄), concentrated and purified by Bond Elut™ chromatography (using 1% to 7.5% EtOH in DCM) to give the title compound as an oil (35 mg, 0.09 mmol); MS: 387.

Example 26



10

1-[2,4-Dimethoxy-6-hydroxyphenylmethyl]-piperidin-4-yl]benzimidazole

To a solution of 2,4-dimethoxy-6-hydroxybenzaldehyde (1.8mg, 10μM) in NMP (100μL) was added a solution of 1-(1*H*-4-piperidin-4-yl)benzimidazole (Method A) (1.0mg, 5μM) and diisopropylethylamine (1μL, 5.5μM) in NMP (100μL). After 1.5h a solution of 15 sodium triacetoxyborohydride (2.8mg, 15μM) in acetonitrile: NMP, 1:1 (100μL) was added. After 16h at room temperature the reaction mixture was concentrated to give the title compound which was identified by LCMS; MS: 368.

Examples 27-28

The procedure described in Example 26 was repeated using the appropriate starting 20 material (shown below) to replace the 2,4-dimethoxy-6-hydroxybenzaldehyde to obtain the compounds described in the following table.

Example No.	Starting Material	Final Product	MS (MH ⁺)
27	4- <i>N,N</i> -Dimethylaminocinnamaldehyde	1-[{3-(4- <i>N,N</i> -Dimethylaminophenyl)prop-2- <i>E</i> -enyl}-piperidin-4-yl]benzimidazole	361

28	2,4-Dimethyl,1- <i>N</i> -phenylpyrrole-3-carboxaldehyde	1-[{(2,4-Dimethyl,1- <i>N</i> -phenylpyrrol-3-yl)methyl}-piperidin-4-yl]benzimidazole	385	

Method A**1-(1*H*-4-Piperidin-4-yl)benzimidazole**

5 A suspension of 1-[1-(phenylmethyloxycarbonyl)-piperidin-4-yl]benzimidazole (Method B) (3.44 g, 9.7 mmol) and 10% palladium on carbon (250 mg) in EtOH (150 ml) was stirred at room temperature under a hydrogen atmosphere (1 atm). After 70h the mixture was filtered through Celite™ and concentrated to give a brown oil. The residue was chromatographed on silica with 10% methanol/ DCM as eluant to give the title compound as an oil (1.95g, 9.7mmol); NMR: 1.9 (m, 4H), 2.7 (m, 2H), 3.1 (m, 2H), 4.4 (m, 1H), 7.2 (m, 2H), 7.6 (m, 2H) and 8.3 (s, 1H); MS: 202.

Method B**1-[1-(Phenylmethyloxycarbonyl)-piperidin-4-yl]benzimidazole**

15 A solution of 2-amino-1-*N*-[1-(phenylmethyloxycarbonyl)-piperidin-4-yl]aniline (Method C) (500 mg, 1.4 mmol), trimethyl orthoformate (1 ml, 9.7 mmol) and *para*-toluenesuphonic acid monohydrate (30 mg, 0.16 mmol) were stirred at 100°C. After 2h the mixture was cooled and water (10 ml) was added. The solution was partitioned with EtOAc (3 x 20 ml) then the organics were combined, washed with water (10 ml), dried (MgSO₄) and concentrated to give the title compound as an oil that did not need further purification (410 mg, 1.2 mmol); NMR: 2.0 (m, 4H), 3.0 (m, 2H), 4.2 (d, 2H), 4.6 (m, 1H), 5.1 (s, 2H), 7.2 (m, 2H), 7.4 (m, 5H), 7.65 (d, 2H) and 8.3 (s, 1H); MS: 336.

Method C**2-Amino-1-*N*-[1-(phenylmethyloxycarbonyl)-piperidin-4-yl]aniline**

25 To a stirred suspension of Raney nickel (510 mg) in THF (40 ml) was added 2-nitro-1-*N*-[1-(phenylmethyloxycarbonyl)-piperidin-4-yl]aniline (Method D) (200 mg, 0.56 mmol) and the mixture was stirred under a hydrogen atmosphere (1 atmosphere). After 15h the mixture was filtered through Celite™, concentrated and purified by column chromatography (eluting with 25% EtOAc/ DCM) to give the title compound as an oil (50 mg, 0.15 mmol);

NMR: 1.3 (m, 2H), 1.9 (m, 2H), 3.0 (m, 2H), 3.3 (m, 2H), 3.9 (m, 1H), 4.1 (d, 1H), 4.45 (br s, 2H), 5.05 (s, 2H), 6.4 (m, 4H) and 7.3 (m, 5H); MS: 326.

Method D

2-Nitro-1-N-[1-(phenylmethyloxycarbonyl)-piperidin-4-yl]aniline

5 A suspension of 2-fluoronitrobenzene (3.52 g, 25 mmol), 4-amino-1-(phenylmethyloxycarbonyl)piperidine† (4.0 g, 17 mmol) and potassium carbonate (2.64 g, 19 mmol) in DMSO (25 ml) was heated to 100°C. After 5h the mixture was poured into ice/water and the resulting yellow solid was collected by filtration and washed with water. The solid was dried to give the title compound as a yellow solid (5.69 g, 16 mmol): NMR: 1.6 (m, 2H), 2.1 (d, 2H), 3.1 (t, 2H), 3.7 (m, 1H), 4.1 (d, 2H), 5.2 (s, 2H), 6.7 (t, 1H), 6.9 (d, 1H), 7.3-7.5 (m, 6H), 8.1 (d, 1H) and 8.2 (dd, 1H); MS: 356.

10

† Compound described in EP-A-0309422

Method E

4-Amino-1-(3R/S-phenylbutyl)piperidine

15 To a solution of 4-*tert*-butoxycarbonylamino-1-(3R/S-phenylbutyl)piperidine (Method F) (13.1g, 39.5 mmol) in DCM (150 ml) was added trifluoroacetic acid (30 ml) dropwise. After 15h, toluene was added and the reaction mixture was concentrated to give the di-trifluoroacetic acid salt of the title compound as an oil (12.8 g, 27.8 mmol); MS: 233.

Method F

4-*tert*-Butoxycarbonylamino-1-(3R/S-phenylbutyl)piperidine

20 To a stirred solution of 4-(*tert*-butoxycarbonylamino)piperidine (45 g, 0.225 mol) in methanol (160 ml) was added 3-phenylbutyraldehyde (36.5 ml, 0.25 mol) followed by acetic acid (15 ml). After 1h, sodium triacetoxyborohydride (71.5 g, 0.34 mol) was added portionwise over 30 mins [Caution: effervescence and exotherm]. After 15h water (60 ml) was added and the total mixture was concentrated to remove methanol. Water (250 ml) was added and the mixture was extracted with EtOAc (3 x 500 ml). The combined organics were washed with water, brine and dried (MgSO_4) to give the title compound as a white solid that was further recrystallised from DCM/ EtOAc (54.1 g, 0.163 mol); M. pt. 220-221°C; NMR: 1.2 (m, 3H), 1.4 (s, 9H), 1.7 (m, 2H), 2.0 (m, 6H), 2.8 (m, 4H), 3.3 (m, 2H), 7.0 (br s, 1H), 7.3 (m, 5H); MS: 333.

25

30

Method G1-Bromo-3-(3,4-dichlorophenyl)-4-(N-methylbenzenesulphonamide)butane

To a solution of 3-(3,4-dichlorophenyl)-4-(N-methylbenzenesulphonamide)butan-1-ol (prepared as described below) (257 mg, 0.66 mmol) in DCM (20 ml) was added carbon 5 tetrabromide (232 mg, 0.7 mmol) followed by triphenylphosphine (183 mg, 0.7 mmol). After 5 hours the solution was concentrated and then purified by Bond ElutTM chromatography (eluting with dichloromethane) to give the title compound as an oil, which solidified on standing (290 mg, 0.64 mmol); NMR: 2.07 (m, 1H), 2.38 (m, 1H), 2.69 (s, 3H), 3.06 (dd, 1H), 3.10 (dd, 1H), 3.17 (m, 1H), 3.40 (m, 2H), 7.07 (dd, 1H), 7.28 (d, 1H), 7.40 (d, 1H), 7.55 (m, 10 3H) and 7.77 (d, 2H).

3-(3,4-Dichlorophenyl)-4-(N-methylbenzenesulphonamide)butan-1-ol

Sodium hydride (57.4 g, 60% dispersion in oil, 1.43 mol) was added to a 3 L, 3-necked flask (fitted with mechanical stirrer, exit needle and condenser) and suspended in THF (900 ml). A solution of 3,4-dichlorophenylacetonitrile (257 g, 1.38 mol) in THF (400 ml) was 15 added to the ice-cooled flask *via* cannula over a period of 1 hour. The mixture was then stirred at room temperature for 1.5 hours during which time there was vigorous gas evolution. The reaction mixture was then ice-cooled and 2-(2-bromoethyl)oxytetrahydropyran (288.5 g, 1.38 mol) was added *via* teflon cannula under nitrogen pressure over a period of 30 mins. After 40 hours the reaction mixture was quenched with ammonium chloride (10 ml), 20 concentrated (to remove the THF) and water was added. The mixture was extracted with DCM and the organic extracts dried (Na₂SO₄), concentrated and distilled under reduced pressure (174°C, 100 mtorr) to give an oil. This residue was purified by flash column chromatography (hexane to 1:1, hexane: DCM) to give 2-(3-cyano-3-[3,4-dichlorophenyl]propyl)oxytetrahydropyran as an oil (210 g, 0.67 mol).

25 Raney nickel (38 g) was placed in a stainless steel bottle and EtOH (100 ml) was added followed by a solution of 2-(3-cyano-3-(3,4-dichlorophenyl)propyl)oxytetrahydropyran (138 g, 0.44 mol) in EtOH (1100 ml) and concentrated ammonium hydroxide (600 ml). The bottle was then shaken under an atmosphere of hydrogen gas (53 psi) and when the pressure fell below 35 psi the flask was repressurised. After 24h the pressure remained constant so the 30 reaction mixture was filtered through CeliteTM and concentrated. Water was added, the mixture was extracted with DCM and then dried (Na₂SO₄) and concentrated to give 2-(3-(3,4-dichlorophenyl)-4-aminobutyl)oxytetrahydropyran as an oil (75 g, 0.24 mol).

To a stirred solution of 2-(3-[3,4-dichlorophenyl]-4-aminobutyl)oxytetrahydropyran (2 g, 6.3 mmol) in DCM (50 ml) was added triethylamine (1.3 ml, 9.4 mmol) followed by benzenesulphonyl chloride (0.82 ml, 6.4 mmol). After 15 hours the reaction mixture was diluted with DCM, washed with hydrochloric acid (0.3M, 50 ml), sodium hydroxide (1M, 20 ml), water (20 ml), dried (Na_2SO_4), concentrated and purified by flash column chromatography (eluting with 1:1 hexane, ether) to give 2-(3-[3,4-dichlorophenyl]-4-(*N*-benzenesulphonamide)butyl)oxytetrahydropyran as an oil (3.02g, 6.3 mmol); MS: 462.

Sodium hydride (0.5 g, 60% dispersion in oil, 12.5 mmol) was washed with petroleum ether and DMF (5 ml) was added. A solution of 2-(3-[3,4-dichlorophenyl]-4-(*N*-benzenesulphonamide)butyl)oxytetrahydropyran (2.6 g, 5.7 mmol) in DMF (15 ml) was then added *via* cannula and the mixture was left to stir until bubbling ceased at which point methyl iodide (0.7 ml, 11.2 mmol) was added in one portion. After 2 hours the reaction was quenched with the dropwise addition of water. Hydrochloric acid (1M, 13 ml) and water (350 ml) were added and the mixture extracted with DCM (3 x 50 ml). The combined organics were washed with water, dried (Na_2SO_4) and concentrated to give 2-(3-[3,4-dichlorophenyl]-4-(*N*-methylbenzenesulphonamide)butyl)oxytetrahydropyran as an oil (2.6 g, 5.5 mmol).

A solution of 2-(3-[3,4-dichlorophenyl]-4-[*N*-methylbenzenesulphonamide]butyl)-oxytetrahydropyran (3g, 6 mmol) in THF (100 ml) and hydrochloric acid (1M, 50 ml). After 60h the solution was concentrated to remove THF, then sodium hydroxide (1M solution, 45 ml) was added followed by saturated sodium bicarbonate and the mixture was extracted with ether (3 x 50 ml). The combined organics were washed with brine, dried (Na_2SO_4), concentrated and purified by flash column chromatography (using ether: hexane, 4:1 as eluent) to give 3-(3,4-dichlorophenyl)-4-(*N*-methylbenzenesulphonamide)butan-1-ol as an oil (1.83 g, 4.7 mmol); MS: 387.

25 **Method H**

The ability of compounds to inhibit the binding of RANTES was assessed by an *in vitro* radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated with 0.1nM iodinated RANTES, scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated RANTES bound to the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated

RANTES was calculated (IC_{50}). All of the compounds of Examples 1-28 had an IC_{50} of less than 50 μ M.

Method I

4-Amino-1-(3,3-diphenylpropyl)piperidine

5 To a solution of 4-*tert*-butoxycarbonylamino-1-*N*-(3,3-diphenylpropyl)piperidine (Method J) (10g, 25 mmol) in DCM (100 ml) was added trifluoroacetic acid (20 ml) dropwise. After 3h, toluene was added and the reaction mixture was concentrated to give the di-trifluoroacetic acid salt of the title compound as an oil (9.7 g, 19 mmol); MS: 295.

Method J

4-*tert*-Butoxycarbonylamino-1-*N*-(3,3-diphenylpropyl)piperidine

To a solution of 4-(Boc-amino) piperidine (10g, 50mmol) in acetonitrile (200ml) was added 3,3-diphenylpropyl bromide (15.1g, 55mmol), *tetra*-butylammonium iodide (2g, 5mmol) and potassium carbonate (15g, 100mmol) and the mixture refluxed. After 5h the reaction mixture was cooled and poured into water. The solution was partitioned with EtOAc and the organic layer dried ($MgSO_4$), concentrated and purified by column chromatography (toluene: EtOAc, 1:1 with 1% triethylamine) to give the title compound as an oil (15.9g, 40mmol); MS: 395.

Method K

4-*tert*-Butoxycarbonylamino-1-(3-S-phenyl-1-butanoic amide)piperidine

20 To a solution of 4-Boc-amino piperidine (2.46g, 12.3 mmol) in DMF (30 mL) was added HATU (4.67g, 12.3 mmol), 3-S-phenyl-1-butanoic acid (2g, 12.2 mmol) and diisopropylethylamine (2.12 mL). The reaction mixture was stirred over night then poured into water and extracted into ethyl acetate. Dried over $MgSO_4$ and evaporated to afford the title compound as a white solid, (4.03 g, 11.6mmol); NMR: 1.20 (6H, m), 1.38 (9H, s), 1.65 (2H, m), 2.60 (2H, m), 3.00 (1H, m), 3.15 (1H, q), 3.40 (1H, m), 3.80 (1H, d, broad), 4.20 (1H, m), 6.80 (1H, m), 7.18 (1H, m), 7.24 (4H, m) MS: 347, 291 (- BOC).

Method L

4-Amino-1-(3-S-phenyl-1-butanoic amide)piperidine hydrochloride

30 To a solution of acetyl chloride (5mL) in methanol (20mL) was added 4-Boc-amino-1-(3-S-phenyl-1-butanoic amide)piperidine (Method K) (1g, 3mmol) and stirred for 1h. The solvents were then evaporated to afford the title compound as a white solid. (850mg, 3mmol); NMR: 1.20 (3H, d), 1.35 (2H, m), 1.41 (1H, m), 1.89 (2H, m), 3.0 (5H, m), 3.90 (1H, d), 4.30 (1H, d), 7.10 (1H, m), 7.20 (4H, m); MS: 247.

Method M**4-Amino-1-(3-S-phenylbutyl)piperidine**

To a solution of 4-amino-1-(3-S-phenylbutyl)piperidine (Method L) (850mg, 3 mmol) in THF (20mL) was added a solution of LiAlH₄ in THF (10 mL of 1.0M solution) and the mixture was refluxed for 5h. After cooling and quenching with aqueous sodium hydroxide the mixture was filtered and partitioned between water and ethyl acetate. The combined organic phase was dried (MgSO₄) and evaporated to afford the title compound as a white solid. (610 mg, 2.6mmol); NMR: 1.20 (4H, m), 1.60 (4H, m), 1.89 (2H, m), 2.10 (2H, m), 2.43 (1H, m), 2.70 (4H, m), 7.10 (3H, m), 7.20 (2H, m); MS: 233.

Method N**2-Amino-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline**

To a stirred solution of 2-nitro-1-*N*-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline (Method O) (765 mg, 2.16 mmol) in ethanol (10 ml) was added 10% Pd on carbon and the mixture was stirred under a hydrogen atmosphere (1 atmosphere). After 5h the reaction mixture was filtered through CeliteTM, concentrated and purified by Bond ElutTM chromatography (using DCM, and 2.5% to 10% EtOH in DCM) to give an oil that still contained impurities. The oil was then purified on an amine retention SCX column eluting first with methanol and then with 2% aqueous ammonia in methanol to give the title compound as an oil (580mg, 1.8 mmol); NMR: 1.2 (d, 3H), 1.4 (m, 2H), 1.7 (m, 2H), 2.0 (m, 6H), 2.8 (m, 3H), 4.05 (m, 1H), 4.4 (m, 2H), 6.4 (m, 4H) and 7.20 (m, 5H); MS: 324.

Method O**2-Nitro-1-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline**

A mixture of 4-amino-1-(3R/S-phenylbutyl)piperidine di-trifluoroacetate (Method E) (1g, 2.17 mmol), 2-fluoronitrobenzene (0.37ml, 3.5 mmol) and potassium carbonate (1.2g, 8.7 mmol) in DMSO (10 ml) was heated at 90°C. After 2h the mixture was poured onto water and extracted with EtOAc (3x200ml). The organics were combined, washed with brine, dried (MgSO₄) and concentrated to give the title compound as an oil (765mg, 2.17 mmol); NMR: 1.2 (d, 3H), 1.5 (m, 2H), 1.7 (m, 2H), 1.9 (m, 2H), 2.2 (m, 4H), 2.7 (m, 4H), 3.6 (m, 1H), 6.75 (t, 1H), 7.20 (m, 6H) and 7.4 (m, 2H); MS: 354.


Method P**2-Acetamido-1-*N*-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline**

A mixture of 2-amino-1-*N*-[1-(3R/S-phenylbutyl)-piperidin-4-yl]aniline (Method N) (80mg, 0.25mmol), acetic acid (0.016ml, 0.28mmol) and EEDQ (68mg, 0.28mmol) in DCM

(3ml) was stirred. After 15h the mixture was concentrated and purified by column chromatography (DCM followed by 2.5% EtOH/ DCM, 5% EtOH/ DCM and finally 5% EtOH/ DCM with added 2% isopropylamine to give the title compound as an oil (60mg, 0.16mmol); NMR: 1.15 (d, 3H), 1.4 (m, 2H), 1.7 (q, 2H), 2.0 (m, 9H), 2.7 (m, 3H), 4.55 (d, 5 1H), 6.5 (t, 1H), 6.65 (d, 1H), 6.95 (t, 1H), 7.20 (m, 6H) and 9.05 (s, 1H); MS: 366.


Method Q

The ability of compounds to inhibit the binding of MIP-1 α was assessed by an *in vitro* radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated 10 with 0.1nM iodinated MIP-1 α , scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated MIP-1 α bound to the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated MIP-1 α was calculated (IC₅₀). All of the compounds of Examples 1, 2, 4, 5, 15, 19, 22, 23 15 and 24 had an IC₅₀ of less than 50 μ M.


Scheme 1

* optionally substituted ring

Scheme 2




* optionally substituted ring

Scheme 3

CLAIMS

1. A compound of formula (I):



5

wherein

A is a 5, 6 or 7 membered ring comprising, respectively, 4, 5 or 6 carbons and one nitrogen which carries a substituent R¹, A being either saturated or including one endocyclic double bond;

X-Y is N=C(R⁵) or N=N;

10 J is N or CR^{2a}; K is N or CR^{2b}; L is N or CR^{2c}; M is N or CR^{2d}; provided that no more than 2 of J, K L and M are N;

R^{2a}, R^{2b}, R^{2c} and R^{2d} are, independently, hydrogen, halo, cyano, nitro, hydroxy, SH, S(O)_pR⁶, NR⁷R⁸, SO₂NR⁹R¹⁰, CONR¹¹R¹², NR¹³SO₂R¹⁴, NR¹⁵COR¹⁶, COR¹⁷, CO₂R¹⁸, NR¹⁹CONR²⁰R²¹, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkenyloxy, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl or heterocyclyl, or phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy, wherein any of the foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy;

20 R¹ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₈ alkenyl or C₃₋₈ alkynyl, each optionally substituted with one or more of: halo, hydroxy, cyano, nitro, C₁₋₆ alkoxy (itself optionally substituted by heterocyclyl or CONR⁶²R⁶³), C₃₋₇ cycloalkyl, NR²²R²³, C(O)R²⁴, NR²⁵SO₂R²⁶, NR²⁷C(O)R²⁸, SO₂NR²⁹R³⁰, CONR³¹R³², NR³³CONR³⁴R³⁵, S(O)_mR⁶⁴, heterocyclyl, heterocyclyloxy, aryl, aryloxy, heteroaryl, heteroaryloxy, 9H-fluorenyl (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl), 9H-xanthenyl (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl) or dibenzo(a,d)cycloheptatrienyl (optionally substituted with halo, hydroxy, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, phenyl or phenyl(C₁₋₄)alkyl);

R³, R^{3a}, R⁴ and R^{4a} are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted by hydroxy or alkoxy), CO₂R³⁶ or CONR³⁷R³⁸ (wherein R³⁶, R³⁷ and R³⁸ are, independently, hydrogen or C₁₋₆ alkyl);

R⁵ is hydrogen, C₁₋₆ alkyl (optionally substituted with cyano, hydroxy, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, COR⁵⁸, SO₂NR⁵⁸R⁵⁹, C(O)NR⁷⁵R⁷⁶, NR⁷⁴COR⁶⁵, NR⁷³SO₂R⁶⁶, NHC(O)NR⁶⁷R⁷², NR⁶⁸R⁶⁹, SO₂R⁷⁷, C(O)R⁷⁸, heterocyclyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, heterocyclyl, heteroaryl, OR⁷⁹, SR⁷⁹, CONR³⁹R⁴⁰, COR³⁹, NR³⁹R⁴⁰, (wherein R³⁹ and R⁴⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl; and R⁷⁹ is C₁₋₆ alkyl (optionally substituted with C₃₋₇ cycloalkyl, phenyl or heteroaryl), C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl or heteroaryl), NR⁷⁰SO₂R⁷¹ or NR⁷⁰C(O)R⁷¹ (wherein R⁷⁰, R⁷³ and R⁷⁴ are, independently, hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or C₃₋₆ cycloalkyl; and R⁷¹ is C₁₋₆ alkyl, C₃₋₇ cycloalkyl, aryl or heteroaryl);

R⁶⁴ is alkyl, cycloalkyl, aryl or heteroaryl;

R¹³, R¹⁵, R¹⁹, R²⁵, R²⁷, R³³, are, independently, hydrogen, C₁₋₆ alkyl or phenyl;

R⁶, R¹⁴ and R²⁶ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl), phenyl or heteroaryl;

R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹⁶, R¹⁷, R¹⁸, R²⁰, R²¹, R²², R²³, R²⁴, R²⁸, R²⁹, R³⁰, R³¹, R³²,

20 R³⁴, R³⁵, R⁵⁸, R⁵⁹, R⁶⁷, R⁶⁸, R⁶⁹, R⁷², R⁷⁵ and R⁷⁶ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, heterocyclyl, CONR⁶⁰R⁶¹, or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

unless specified otherwise, the foregoing aryl, phenyl and heteroaryl moieties are

25 optionally substituted with halo, cyano, nitro, hydroxy, S(O)_qR⁴¹, NR⁴²R⁴³,

SO₂NR⁴⁴R⁴⁵, CONR⁴⁶R⁴⁷, NR⁴⁸SO₂R⁴⁹, NR⁵¹COR⁵², COR⁵³, CO₂R⁵⁴,

NR⁵⁵CONR⁵⁶R⁵⁷, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,

C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkyl, phenyl, phenyl(C₁₋₄)alkyl,

phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl,

30 heteroaryloxy or heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, cyano,

C₁₋₄ alkyl or C₁₋₄ alkoxy;

R⁴⁸, R⁵¹ and R⁵⁵ are, independently, hydrogen, C₁₋₆ alkyl or phenyl;

R⁴¹, R⁴⁹ R⁶⁶ are, independently, alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁵², R⁵³, R⁵⁴, R⁵⁶, R⁵⁷, R⁶⁰, R⁶¹, R⁶², R⁶³ and R⁶⁵ are, independently, hydrogen or alkyl (optionally substituted by halo, hydroxy, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy or phenyl (itself optionally substituted by halo, hydroxy, cyano, C₁₋₄ alkyl or C₁₋₄ alkoxy)), phenyl or heteroaryl;

the pairs of substituents: R⁷ and R⁸, R⁹ and R¹⁰, R¹¹ and R¹², R²⁰ and R²¹, R²² and R²³, R²⁹ and R³⁰, R³¹ and R³², R³⁴ and R³⁵, R³⁷ and R³⁸, R³⁹ and R⁴⁰, R⁴² and R⁴³, R⁴⁴ and R⁴⁵, R⁴⁶ and R⁴⁷, R⁵⁶ and R⁵⁷, R⁵⁸ and R⁵⁹, R⁷⁵ and R⁷⁶, R⁶⁷ and R⁷² and R⁶⁸ and R⁶⁹ may, independently, join to form a ring and such a ring may also comprise an oxygen, sulphur or nitrogen atom;

R⁷⁷ and R⁷⁸ are, independently, *N*-linked heterocyclyl;

where for any of the foregoing heterocyclic groups having a ring -N(H)- moiety, that -N(H)- moiety may be optionally substituted by C₁₋₄ alkyl (itself optionally substituted by hydroxy), C(O)(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ or SO₂(C₁₋₄ alkyl);

m, p and q are, independently, 0, 1 or 2;

a ring nitrogen and/or sulphur atom is optionally oxidised to form an *N*-oxide and/or an *S*-oxide;



or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 wherein A is piperidinyl.
- 25 3. A compound as claimed in claim 1 or 2 wherein X-Y is N=C(R⁵), and wherein R⁵ is as defined in claim 1.
4. A compound as claimed in claim 1, 2 or 3 wherein R³, R^{3a}, R⁴ and R^{4a} are all hydrogen.
- 30 5. A compound as claimed in claim 1, 2, 3 or 4 wherein J is CR^{2a}; K is CR^{2b}; L is CR^{2c}; and M is CR^{2d}; wherein R^{2a}, R^{2b}, R^{2c} and R^{2d} are, independently, hydrogen, halogen, cyano, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂.

6. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein R⁵ is hydrogen or C₁₋₄ alkyl.


7. A compound as claimed in any one of the preceding claims wherein R¹ is CR⁸⁰R⁸¹CR⁸²R⁸³R⁸⁴; R⁸⁴ is OR⁸⁵, NR⁸⁶R⁸⁷ or CR⁸⁸R⁸⁹R⁹⁰; R⁸⁰, R⁸¹, R⁸², R⁸³ and R⁸⁸ are, independently, hydrogen or C₁₋₄ alkyl (for example methyl); R⁸⁵, R⁸⁷ and R⁸⁹ are phenyl or heteroaryl; R⁸⁶ is hydrogen, C₁₋₄ alkyl, phenyl, heteroaryl, C(O)phenyl or C(O)heteroaryl; and R⁹⁰ is C₁₋₄ alkyl, phenyl, heteroaryl, heterocyclyl, phenoxy, heteroaryloxy, NHC(O)(C₁₋₆ alkyl), NHC(O)phenyl, NHC(O)heteroaryl, C₃₋₇ cycloalkyl, CH₂C(O)(C₁₋₆ alkyl), NHC(O)NH(C₁₋₆ alkyl), NHC(O)O(C₁₋₆ alkyl); wherein the foregoing phenyl and heteroaryl groups and moieties are optionally substituted by halogen (especially chlorine or fluorine) or CF₃.

8. A compound of formula (Ib') or (Ic'):



15 wherein R¹ is as defined in claim 1 or 7; R⁵ is as defined in claim 1 or 6; and the meanings of R^{2a'} and R^{2b'} are, independently, selected from the list recited above for R^{2a} and R^{2b} in claim 1 or 5.

9. A compound of formula (Ih):




wherein R¹ is CR⁸⁰R⁸¹CR⁸²R⁸³R⁸⁴; R⁸⁴ is OR⁸⁵, NR⁸⁶R⁸⁷ or CR⁸⁸R⁸⁹R⁹⁰; R⁸⁰, R⁸¹, R⁸², R⁸³ and R⁸⁸ are, independently, hydrogen or C₁₋₄ alkyl; R⁸⁵, R⁸⁷ and R⁸⁹ are phenyl or heteroaryl; R⁸⁶ is hydrogen, C₁₋₄ alkyl, phenyl, heteroaryl, C(O)phenyl or C(O)heteroaryl; R⁹⁰ is C₁₋₄ alkyl, phenyl, heteroaryl, heterocyclyl, phenoxy, heteroaryloxy, NHC(O)(C₁₋₆ alkyl), NHC(O)phenyl, NHC(O)heteroaryl, C₃₋₇ cycloalkyl, CH₂C(O)(C₁₋₆ alkyl), NHC(O)NH(C₁₋₆ alkyl) or NHC(O)O(C₁₋₆ alkyl); R^{2a}, R^{2b}, R^{2c} and R^{2d} are, independently, hydrogen, halogen, cyano, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂; and, R⁵ is hydrogen or C₁₋₄ alkyl; wherein the foregoing phenyl and heteroaryl groups and moieties are optionally substituted by halogen or CF₃.

10. A process for preparing a compound of formula (I), wherein A is piperidine.


15 comprising:

i. cyclising a compound of formula (IIa):




in the presence of NaNO₂ and dilute hydrochloric acid as 0-5°C to produce a triazole ring; or in the presence of R⁵CO₂H in refluxing toluene to produce an imidazole ring;

20 ii. reacting a compound of formula (VIIa):




with a compound of formula R^1LG , wherein LG is a leaving group, in the presence of a base; or,

iii. reacting a compound of formula (V):



5

with a compound of formula (VI)



wherein LG is a leaving group, in the presence of a base.

10 11. A pharmaceutical composition comprising a compound of formula (I), (Ib) or (Ih), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

15 12. A compound of formula (I), (Ib) or (Ih), or a pharmaceutically acceptable salt thereof, for use as a medicament.

13. The use of a compound of formula (I), (Ib) or (Ih), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in modulating a CCR5 receptor.

14. The use of a compound of formula (I), (Ib) or (Ih), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating asthma, transplant rejection, rheumatoid arthritis, atherosclerosis, psoriasis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, glomerulonephritis, chronic obstructive pulmonary disease, cerebral malaria, human immunodeficiency virus infection and acquired immune deficiency syndrome in a warm blooded animal.
5
15. A method of treating a CCR5 mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih) and (Ij), or a pharmaceutically acceptable salt thereof.
10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00470

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 235/04, C07D 249/18, A61K 31/4192, A61K 31/4184, A61K 31/445,
A61P 31/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0059502 A1 (MERCK & CO. INC.), 12 October 2000 (12.10.00), claims 1-39, STN-CAS ONLINE RN 301211-11-0, 3011211-13-2, 301211-18-7, 301211-37-0, 301211-39-2 --	1-15
E,X	WO 0125200 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 12 April 2001 (12.04.01), claim 7, STN CAS ONLINE RN 130017-35-5, RN 333991-79-0 --	1-15
P,X	WO 0038680 A1 (PFIZER, INC.), 6 July 2000 (06.07.00), claim 5, STN CAS ONLINE RN-280761-49-1, RN 280762-52-9 --	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 June 2001

29-06-2001

Name and mailing address of the ISA

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Fernando Farieta/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00470

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0076514 A1 (MERCK & CO. INC.), 21 December 2000 (21.12.00), claim 26, STN CAS ONLINE RN 313707-32-3 --	1-15
X	WO 9917773 A1 (SMITHKLINE BEECHAM CORPORATION), 15 April 1999 (15.04.99), page 5 - page 10 --	1-15
A	WO 9904794 A1 (MERCK & CO. INC.), 4 February 1999 (04.02.99), page 226, claim 19 -- -----	1-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SEO1/00471

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: **14-15** because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No. PCT/SE01/00470

Claims 14,15 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/05/01

International application No.

PCT/SE 01/00470

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0059502 A1	12/10/00	AU 4197900 A		23/10/00
WO 0125200 A1	12/04/01	NONE		
WO 0038680 A1	06/07/00	AU 1290400 A	31/07/00	
		AU 1675100 A	31/07/00	
		EP 1013276 A	28/06/00	
		GB 9828420 D	00/00/00	
		JP 2000212159 A	02/08/00	
		WO 0039125 A	06/07/00	
		GB 9921375 D	00/00/00	
WO 0076514 A1	21/12/00	AU 5600100 A	02/01/01	
WO 9917773 A1	15/04/99	AU 9790198 A	27/04/99	
		EP 1037635 A	27/09/00	
		ZA 9809083 A	07/04/99	
WO 9904794 A1	04/02/99	AU 8576098 A	16/02/99	
		EP 0971887 A	19/01/00	
		EP 1003514 A	31/05/00	
		GB 9800958 D	00/00/00	
		US 6136827 A	24/10/00	